Lasofoxifene and cardiovascular events in postmenopausal women with osteoporosis: Five-year results from the Postmenopausal Evaluation and Risk Reduction with Lasofoxifene (PEARL) trial.
Ensrud
Kristine
K
VA Medical Center, Minneapolis, MN, USA. ensru001@umn.edu
LaCroix
Andrea
A
Thompson
John R
JR
Thompson
David D
DD
Eastell
Richard
R
Reid
David M
DM
Vukicevic
Slobodan
S
Cauley
Jane
J
Barrett-Connor
Elizabeth
E
Armstrong
Roisin
R
Welty
Francine
F
Cummings
Steven
S